Differing national interpretations of the IVD (in vitro diagnostic) Directive will test manufacturers' ability to comply
This article was originally published in Clinica
The Medical Devices Directive was supposed to create a single European regulatory environment for such products throughout the European Economic Area. But differences in the way individual health authorities have transposed it mean that in practice requirements for manufacturers can vary considerably from country to country. The same will be true of the In Vitro Diagnostics Directive, which has technically just come into force. Maureen Kenny reports.
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.